Rare disease patients know what it's like to go without a diagnosis despite enduring symptoms. Doctors often don't recognize the disorders for a number of reasons, whether that's the similarity…
Just about two years ago, Jane Warrimer began experiencing abnormal menstruation. Her period was no longer regular; her bleeding lasted for weeks at a time. After pursuing an IUD, Jane…
U.S. News carried an article reporting that in a recent study, researchers have identified minute amounts of cancer (organoids) in fallopian tube tissue. The significance of the discovery is that…
In a news release from January 24, 2022, immuno-pharma company AIM ImmunoTech Inc. ("AIM") shared that positive clinical data was now published. The data, which you can find in Clinical Cancer…
It is no secret that medical research can provide crucial insights into disease pathology, prognostic factors, and patient outcomes. Recently, a research team from Hokkaido University in Sapporo, Japan dove…
Targeted Oncology recently published a report citing a promising class of drugs to treat recurrent platinum-resistant ovarian cancer (PROC), often associated with a poor prognosis. PROC eventually occurs to a…
How do cytotoxic T lymphocytes (TILs) play a role in ovarian cancer outcomes? What underlying biological activities or cellular interactions help stimulate TILs to destroy or damage cancerous cells? According…
A new method to differentiate between two gynecologic tumors, malignant epithelial ovarian tumors (MEOTs) and borderline epithelial ovarian tumors (BEOTs), has been created by Chinese scientists from the Suzhou Institute…
According to a recent article from the Irish Medical Times, a combination of surgery and platinum-based chemotherapy is the best treatment for patients with advanced ovarian cancer. Ovarian Cancer Ovarian…
IMV Inc. recently presented two posters at the AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics showcasing their DPX delivery platform's immunotherapeutic capabilities. IMV Inc. IMV Inc. is…
Sometimes, treatments used in conjunction with each other can confer benefits for patients. According to the Cancer Network, for example, treating platinum-resistant ovarian cancer using nemvaleukin alfa and pembrolizumab (Keytruda)…
September will soon come to a close, but did you know that this month is also Ovarian Cancer Awareness Month? According to a story from MSN, Michelle Barrenechea, an EMT…
Recent data published in Gynecologic Oncology has confirmed the safety of olaparib for the treatment of advanced, BRCA-mutated, newly diagnosed ovarian cancer. This data came from the Phase 3 SOLO1 trial,…
Normally, Fast Track is an FDA process designed to facilitate and expedite the development and review of drugs or biologics intended to treat rare or serious conditions. Recently, Healio…
Unfortunately, recurrent ovarian cancer can be difficult to treat and often comes with a poor prognosis. However, according to a news release from biopharmaceutical company IMV Inc. ("IMV"), the company…
BeiGene has just announced that China has given conditional approval to Pamiparib, a PARP inhibitor used as a therapy for BRCA associated ovarian cancer, fallopian tube cancer, and primary peritoneal…
Poly ADP ribose polymerase (PARP) inhibitors are targeted cancer therapies which block PARP, an enzyme. Normally, PARP plays a role in DNA repair. Thus, inhibiting PARP prevents cancer cells from…
In China, the Conditional Approval process allows for new drugs to be marketed and developed based on an urgent and unmet need. For example, drugs which treat patients with rare…
On April 28th, the virtual World Orphan Drug Congress USA 2021 was held. The program featured a variety of subjects relevant to the development of orphan drugs and the rare…
Welcome to the Rare Classroom, a new series from Patient Worthy. Rare Classroom is designed for the curious reader who wants to get informed on some of the rarest, most…
During the Society of Gynecological Oncology 2021 Virtual Annual Meeting on Women’s Cancer, researchers presented data from the Phase 2 OVARIO clinical trial. According to Cancer Network, the trial evaluated…
Dr. Oliver Dorigo of the Stanford University Medical Center was the medical source for an article featured in Oncology. Dr. Dorigo explained that if a woman with ovarian cancer has…
Welcome to Study of the Week from Patient Worthy. In this segment, we select a study we posted about from the previous week that we think is of particular interest…
Welcome to study of the week, a new series from Patient Worthy. In this segment, we select a study we posted about from the previous week that we think is…
According to a story from Targeted Oncology, Dr. Bradley Monk talked about the importance of molecular testing in determining the treatment course for ovarian cancer at the Targeted Oncology Case…
© Copyright Patient Worthy
Sign Up With a Patient Worthy Account and Share Your Rare Story
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
